PURPOSE: We investigated the prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) on day 1 in patients with the acute respiratory distress syndrome (ARDS) for intensive care unit (ICU) mortality and compared it with established disease severity scores on day 1. METHODS: suPAR was determined batchwise in plasma obtained within 24 h after admission. RESULTS: 632 ARDS patients were included. Significantly (P = 0.02) higher median levels of suPAR were found with increasing severity of ARDS: 5.9 ng/ml [IQR 3.1-12.8] in mild ARDS (n = 82), 8.4 ng/ml [IQR 4.1-15.0] in moderate ARDS (n = 333), and 9.0 ng/ml [IQR 4.5-16.0] in severe ARDS (n = 217). Non-survivors had higher median levels of suPAR [12.5 ng/ml (IQR 5.1-19.5) vs. 7.4 ng/ml (3.9-13.6), P < 0.001]. The area under the receiver operator characteristic curve (ROC-AUC) for mortality of suPAR (0.62) was lower than the ROC-AUC of the APACHE IV score (0.72, P = 0.007), higher than that of the ARDS definition classification (0.53, P = 0.005), and did not differ from that of the SOFA score (0.68, P = 0.07) and the oxygenation index (OI) (0.58, P = 0.29). Plasma suPAR did not improve the discrimination of the established disease severity scores, but did improve net reclassification of the APACHE score (29%), SOFA score (23%), OI (38%), and Berlin definition classification (39%). CONCLUSION: As a single biological marker, the prognostic value for death of plasma suPAR in ARDS patients is low. Plasma suPAR, however, improves the net reclassification, suggesting a potential role for suPAR in ICU mortality prediction models.
PURPOSE: We investigated the prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) on day 1 in patients with the acute respiratory distress syndrome (ARDS) for intensive care unit (ICU) mortality and compared it with established disease severity scores on day 1. METHODS:suPAR was determined batchwise in plasma obtained within 24 h after admission. RESULTS: 632 ARDS patients were included. Significantly (P = 0.02) higher median levels of suPAR were found with increasing severity of ARDS: 5.9 ng/ml [IQR 3.1-12.8] in mild ARDS (n = 82), 8.4 ng/ml [IQR 4.1-15.0] in moderate ARDS (n = 333), and 9.0 ng/ml [IQR 4.5-16.0] in severe ARDS (n = 217). Non-survivors had higher median levels of suPAR [12.5 ng/ml (IQR 5.1-19.5) vs. 7.4 ng/ml (3.9-13.6), P < 0.001]. The area under the receiver operator characteristic curve (ROC-AUC) for mortality of suPAR (0.62) was lower than the ROC-AUC of the APACHE IV score (0.72, P = 0.007), higher than that of the ARDS definition classification (0.53, P = 0.005), and did not differ from that of the SOFA score (0.68, P = 0.07) and the oxygenation index (OI) (0.58, P = 0.29). Plasma suPAR did not improve the discrimination of the established disease severity scores, but did improve net reclassification of the APACHE score (29%), SOFA score (23%), OI (38%), and Berlin definition classification (39%). CONCLUSION: As a single biological marker, the prognostic value for death of plasma suPAR in ARDS patients is low. Plasma suPAR, however, improves the net reclassification, suggesting a potential role for suPAR in ICU mortality prediction models.
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher Journal: Crit Care Med Date: 1998-11 Impact factor: 7.598
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: Niall D Ferguson; Eddy Fan; Luigi Camporota; Massimo Antonelli; Antonio Anzueto; Richard Beale; Laurent Brochard; Roy Brower; Andrés Esteban; Luciano Gattinoni; Andrew Rhodes; Arthur S Slutsky; Jean-Louis Vincent; Gordon D Rubenfeld; B Taylor Thompson; V Marco Ranieri Journal: Intensive Care Med Date: 2012-08-25 Impact factor: 17.440
Authors: V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky Journal: JAMA Date: 2012-06-20 Impact factor: 56.272
Authors: Alexander Koch; Sebastian Voigt; Carsten Kruschinski; Edouard Sanson; Hanna Dückers; Andreas Horn; Eray Yagmur; Henning Zimmermann; Christian Trautwein; Frank Tacke Journal: Crit Care Date: 2011-02-16 Impact factor: 9.097
Authors: Lieuwe D Bos; Olaf L Cremer; David S Y Ong; Eliana B Caser; Carmen S V Barbas; Jesus Villar; Robert M Kacmarek; Marcus J Schultz Journal: Intensive Care Med Date: 2015-07-23 Impact factor: 17.440
Authors: Zhiguo Zhao; Nancy Wickersham; Kirsten N Kangelaris; Addison K May; Gordon R Bernard; Michael A Matthay; Carolyn S Calfee; Tatsuki Koyama; Lorraine B Ware Journal: Intensive Care Med Date: 2017-06-07 Impact factor: 17.440
Authors: L D Bos; L R Schouten; L A van Vught; M A Wiewel; D S Y Ong; O Cremer; A Artigas; I Martin-Loeches; A J Hoogendijk; T van der Poll; J Horn; N Juffermans; C S Calfee; M J Schultz Journal: Thorax Date: 2017-04-27 Impact factor: 9.139
Authors: Chase T Schultz-Swarthfigure; Philip McCall; Robert Docking; Helen F Galley; Benjamin Shelley Journal: Interact Cardiovasc Thorac Surg Date: 2021-01-22